ROTHSCHILD & CO ASSET MANAGEMENT US INC. - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 222 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.

Quarter-by-quarter ownership
ROTHSCHILD & CO ASSET MANAGEMENT US INC. ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q4 2022$6,463,820
+29.4%
139,517
+15.6%
0.10%
+15.3%
Q3 2022$4,997,000
+70.3%
120,667
+145.4%
0.08%
+88.9%
Q2 2022$2,934,000
-8.0%
49,173
+12.0%
0.04%
+9.8%
Q1 2022$3,189,000
-67.6%
43,918
-65.1%
0.04%
-71.7%
Q2 2020$9,831,000
+56.0%
125,683
-11.4%
0.14%
+48.0%
Q1 2020$6,303,000
-7.3%
141,870
-10.9%
0.10%
+38.0%
Q4 2019$6,799,000
+47.7%
159,183
+48.0%
0.07%
+42.0%
Q3 2019$4,603,000
-31.1%
107,590
+2.2%
0.05%
-29.6%
Q2 2019$6,685,000
+73.5%
105,275
+89.5%
0.07%
+73.2%
Q1 2019$3,852,000
+209.4%
55,540
+93.9%
0.04%
+173.3%
Q4 2018$1,245,000
-43.6%
28,641
-0.9%
0.02%
-34.8%
Q3 2018$2,207,000
-1.9%
28,907
-1.2%
0.02%
-4.2%
Q2 2018$2,250,000
+89.7%
29,267
+25.8%
0.02%
+84.6%
Q1 2018$1,186,000
+1.5%
23,269
-7.6%
0.01%
+8.3%
Q4 2017$1,168,000
-18.9%
25,176
-7.0%
0.01%
-25.0%
Q3 2017$1,441,000
-15.4%
27,059
-1.4%
0.02%
-15.8%
Q2 2017$1,704,000
-13.0%
27,436
-5.0%
0.02%
-13.6%
Q1 2017$1,958,000
-10.2%
28,884
-6.8%
0.02%
-21.4%
Q4 2016$2,180,000
+449.1%
31,004
+453.6%
0.03%
+300.0%
Q3 2016$397,000
+70.4%
5,600
+17.4%
0.01%
+75.0%
Q2 2016$233,0004,7700.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q2 2022
NameSharesValueWeighting ↓
First Light Asset Management, LLC 437,512$31,772,0002.80%
RTW INVESTMENTS, LP 1,373,284$99,728,0002.06%
Rock Springs Capital Management LP 1,028,109$74,661,0001.88%
Privium Fund Management B.V. 112,727$8,186,0001.81%
Avidity Partners Management LP 869,000$63,107,0001.31%
SUVRETTA CAPITAL MANAGEMENT, LLC 525,100$38,133,0001.16%
Boxer Capital, LLC 200,000$14,524,0000.75%
SECTOR GAMMA AS 46,221$3,357,0000.73%
FEDERATED HERMES, INC. 3,987,728$289,589,0000.65%
EMERALD ADVISERS, LLC 223,952$16,263,0000.62%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders